MEI Pharma to rebrand as ‘Lite Strategy’: Unveiling a Bold Litecoin Investment

MEI Pharma, a Nasdaq-listed biopharmaceutical company, is set for a major transformation. The firm, known for its significant Litecoin holdings, will be rebranding as ‘Lite Strategy,’ signifying a dramatic shift in focus towards this cryptocurrency and highlighting a bold investment strategy. This move, reported by Business Wire, signifies the increasing integration of digital assets into corporate finance. 929,000 LTC currently represent a significant portion of MEI Pharma’s reserves, demonstrating an active and strategic approach to crypto-asset management.